Biotin-avidin interaction-based screening assay for Alzheimer's β-peptide oligomer inhibitors

Analytical Biochemistry

Volumn 356, Issue 2, 2006, Pages 265-272

  LeVine III, Harry ^a  

^a National Institute on Aging Gerontology Research Center   (United States)

Author keywords

Alzheimer's; Amyloid; High throughput; Misfolding; Single site assay

Indexed keywords

ANTIBODIES; COENZYMES; GLYCOPROTEINS; NEURODEGENERATIVE DISEASES; PEPTIDES;

ALZHEIMER'S; AMYLOID; HIGH THROUGHPUT; MISFOLDING; SINGLE SITES;

OLIGOMERS;

1,1 BIS(4 ANILINO)NAPHTHALENE 5,5 DISULFONIC ACID; 2 AMINO 4 CHLOROPHENOL; 2 [4' (METHYLAMINO)PHENYL]BENZOTHIAZOLE; 4 AMINOPHENOL; AMYLOID BETA PROTEIN; AVIDIN; BENZOTHIAZOLE DERIVATIVE; BIOTIN; CONGO RED; CURCUMIN; IBUPROFEN; NAPROXEN; NORDIHYDROGUAIARETIC ACID; OLIGOMER; PHENOL DERIVATIVE; POLYSORBATE 20; RESVERATROL; STREPTAVIDIN; SULFONIC ACID DERIVATIVE; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIOTINYLATION; CHEMICAL INTERACTION; HIGH THROUGHPUT SCREENING; IMMUNOASSAY; OLIGOMERIZATION; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 33747891817     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2006.04.036     Document Type: Article

References (34)

1. Glabe C.C. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric, and fibrillar Aβ. Subcell. Biochem. 38 (2005) 167-177
2. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
3. Senior K. Soluble amyloid oligomers: a common cause of neurodegeneration?. Lancet Neurol. 2 (2003) 330
4. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
5. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., Podlisny M.B., Cleary J.P., Ashe K.H., Rowan M.J., and Selkoe D.J. The role of cell-derived oligomers of Aβ in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 33 (2005) 1087-1090
6. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
7. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
8. Wang J., Dickson D.W., Trojanowski J.Q., and Lee V.M. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158 (1999) 328-337
9. Haes A.J., Chang L., Klein W.L., and Van Duyne R.P. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J. Am. Chem. Soc. 127 (2005) 2264-2271
10. Georganopoulou D.G. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 102 (2005) 2273-2276
11. Teller J.K., Russo C., DeBusk L.M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D.M., Tabaton M., and Gambetti P. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2 (1996) 93-95
12. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
13. El Agnaf O.M., Mahil D.S., Patel B.P., and Austen B.M. Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 273 (2000) 1003-1007
14. Howlett D., Cutler P., Heales S., and Camilleri P. Hemin and related porphyrins inhibit β-amyloid aggregation. FEBS Lett. 417 (1997) 249-251
15. LeVine III H. Alzheimer's β-peptide oligomer formation at physiologic concentrations. Anal. Biochem. 335 (2004) 81-90
16. Frey A., Meckelein B., Externest D., and Schmidt M.A. A stable and highly sensitive 3,3′,5,5′-tetramethylbenzidine-based substrate reagent for enzyme-linked immunosorbent assays. J. Immunol. Methods 233 (2000) 47-56
17. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., and Hillen H. Globular amyloid β-peptide oligomer: a homogeneous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95 (2005) 834-847
18. Huang S.C., Stump M.D., Weiss R., and Caldwell K.D. Binding of biotinylated DNA to streptavidin-coated polystyrene latex: effects of chain length and particle size. Anal. Biochem. 237 (1996) 115-122
19. Kada G., Falk H., and Gruber H.J. Accurate measurement of avidin and streptavidin in crude biofluids with a new, optimized biotin-fluorescein conjugate. Biochim. Biophys. Acta 1427 (1999) 33-43
20. Bitan G., and Teplow D.B. Rapid photochemical cross-linking: a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem. Res. 37 (2004) 357-364
21. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
22. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100 (2003) 10417-10422
23. Moss M.A., Varvel N.H., Nichols M.R., Reed D.K., and Rosenberry T.L. Nordihydroguaiaretic acid does not disaggregate β-amyloid(1-40) protofibrils but does inhibit growth arising from direct protofibril association. Mol. Pharmacol. 66 (2004) 592-600
24. De Felice F.G., Vieira M.N., Saraiva L.M., Figueroa-Villar J.D., Garcia-Abreu J., Liu R., Chang L., Klein W.L., and Ferreira S.T. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization. FASEB J. 18 (2004) 1366-1372
25. Ferrao-Gonzales A.D., Robbs B.K., Moreau V.H., Ferreira A., Neto L.J., Valente A.P., Almeida F.C., Silva J.L., and Foguel D. Controlling β-amyloid oligomerization by the use of naphthalene sulfonates: trapping low-molecular-weight oligomeric species. J. Biol. Chem. 280 (2005) 34747-34754
26. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005) 5892-5901
27. Carnero-Ruiz C., Molina-Bolivar J.A., Aguiar J., MacIsaac G., Moroze S., and Palepu R. Effect of ethylene glycol on the thermodynamic and micellar properties of Tween 20. Colloid Polym. Sci. 271 (2003) 531-541
28. Kayed R., Sokolov Y., Edmonds B., MacIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein mis-folding diseases. J. Biol. Chem. 279 (2004) 46363-46366
29. Laitinen O.H., Nordlund H.R., Hytonen V.P., Uotila S.T., Marttila A.T., Savolainen J., Airenne K.J., Livnah O., Bayer E.A., Wilchek M., and Kulomaa M.S. Rational design of an active avidin monomer. J. Biol. Chem. 278 (2003) 4010-4014
30. LeVine III H. Soluble multimeric Alzheimer β(1-40) pre-amyloid complexes in dilute solution. Neurobiol. Aging 16 (1995) 755-764
31. Bitan G., Lomakin A., and Teplow D.B. Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276 (2001) 35176-35184
32. Tan L.P., and Yao S.Q. Intein-mediated, in vitro, and in vivo protein modifications with small molecules. Protein Peptide Lett. 12 (2005) 769-775
33. Sibler A.P., Kempf E., Glacet A., Orfanoudakis G., Bourel D., and Weiss E. In vivo biotinylated recombinant antibodies: high efficiency of labelling and application to the cloning of active anti-human IgG1 Fab fragments. J. Immunol. Methods 224 (1999) 129-140
34. Beckett D., Kovaleva E., and Schatz P.J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 8 (1999) 921-929